Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 19/20 | 0.80 |
| ▸ | CRBN | Q96SW2 | 19/20 | 0.80 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.59 |
| ▸ | TNF | P01375 | 1/20 | 0.59 |
| ▸ | IL1B | P01584 | 1/20 | 0.59 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.59 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL476904 | 1.00 | DDB1 (0.80) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL476960 | 0.91 | DDB1 (0.81) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL30041341 | 0.91 | DDB1 (0.81) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL2382971 | 0.91 | DDB1 (0.78) | DDB1CRBNIKZF3TNFIL1B | |
| Hydrochloric Acid SCHEMBL2381756 | 0.90 | DDB1 (0.77) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL2384835 | 0.90 | DDB1 (0.77) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL5136914 | 0.90 | DDB1 (0.83) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL20118479 | 0.89 | DDB1 (0.79) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL5549995 | 0.89 | DDB1 (0.75) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL2382251 | 0.89 | DDB1 (0.75) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125449-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | JUNO THERAPEUTICS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12583904-B2 | Articles of manufacture and methods for treatment using adoptive cell therapy | JUNO THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4611798-A1 | METHODS OF TREATMENT WITH T CELL THERAPY AND IMMUNOMODULATORY AGENT MAINTENANCE THERAPY | CELGENE CORPORATION (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4543923-A1 | TREATMENT METHODS FOR SECOND LINE THERAPY OF CD19-TARGETED CAR T CELLS | Juno Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20250011387-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | JUNO THERAPEUTICS, INC. (US) | 2025-01-09 | — | — | US | disclosed |
| CN-118662614-A | Articles and methods of treatment using adoptive cell therapy | 朱诺治疗学股份有限公司 | 2024-09-20 | — | — | CN | disclosed |
| WO-2024097905-A1 | METHODS OF TREATMENT WITH T CELL THERAPY AND IMMUNOMODULATORY AGENT MAINTENANCE THERAPY | CELGENE CORPORATION (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-3886875-B1 | METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | JUNO THERAPEUTICS INC (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-111225675-B | Articles and methods of treatment using adoptive cell therapy | 朱诺治疗学股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023250400-A1 | TREATMENT METHODS FOR SECOND LINE THERAPY OF CD19-TARGETED CAR T CELLS | JUNO THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| CN-115282165-A | Natural killer cells from placenta | 细胞结构公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-115137753-A | Natural killer cells from placenta | 细胞结构公司 | 2022-10-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011387-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | ICOS, PBK, BCL6 | DDB1 3053/4885CRBN 222/4885IKZF3 65/4885 |
| US-12583904-B2 | Articles of manufacture and methods for treatment using adoptive cell therapy | CD4, CD2, ICOS | DDB1 4105/4885CRBN 758/4885IKZF3 131/4885 |
| US-20260125449-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | MALT1, BCL9, ICOS | DDB1 4720/4885CRBN 134/4885IKZF3 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.